Answer
Lunsumio (mosunetuzumab) is contraindicated in patients with hypersensitivity to mosunetuzumab or any excipient listed in section 6.1 of its SmPC.
Sources for this answer
- Lunsumio 1 mg and 30 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.3 Contraindications · Version 11Document updated
Sources checked